Insights from a multidisciplinary heart team for highest-risk valve disease
MHT evaluation facilitates individualized treatment strategies by distinguishing patients who may benefit from intervention despite high procedural risk, while sparing those unlikely to benefit.
Authors
- Thomas G. Pickering (ORCID: https://orcid.org/0009-0001-6369-3807)
- Molly Szerlip (ORCID: https://orcid.org/0000-0002-4907-1825)
- Emily Shih (ORCID: https://orcid.org/0000-0002-2426-513X)
- Lee Hafen
- W. F. Brinkman
- Jennie Hocking (ORCID: https://orcid.org/0000-0001-7158-5470)
- Ghadi Moubarak (ORCID: https://orcid.org/0009-0002-9280-5238)
- Srinivasa P. Potluri (ORCID: https://orcid.org/0009-0002-3645-3506)
- Julius I. Ejiofor
- Timothy George (ORCID: https://orcid.org/0000-0003-3231-2159)
- Kelley A. Hutcheson
- Justin M. Schaffer (ORCID: https://orcid.org/0000-0002-5778-6249)
- Karim Al‐Azizi (ORCID: https://orcid.org/0000-0003-0195-4984)
- Talia Meidan (ORCID: https://orcid.org/0000-0001-6323-8911)
- Garrett Klutts (ORCID: https://orcid.org/0000-0001-6313-9198)
- William P. Ryan
- John J. Squiers (ORCID: https://orcid.org/0000-0003-0608-9934)
- John B. Eisenga (ORCID: https://orcid.org/0000-0003-0950-8620)
- Austin Kluis (ORCID: https://orcid.org/0000-0001-7452-8906)
- John Michael DiMaio (ORCID: https://orcid.org/0000-0002-6064-5869)
- Rahul Sawhney (ORCID: https://orcid.org/0000-0001-5580-0396)
- David Moore
- Katherine Harrington
- Robert L. Smith (ORCID: https://orcid.org/0000-0002-3186-1001)
- Kyle McCullough (ORCID: https://orcid.org/0000-0001-8984-4354)
- Cody W. Dorton (ORCID: https://orcid.org/0009-0003-5789-2986)
Institutions
- Baylor Medical Center at Garland (US)
- Heart Hospital Baylor Plano (US)
- Baylor Scott & White Health (US)
- Texas A&M University (US)
Publication Details
- Journal
- Baylor University Medical Center Proceedings
- Published
- 2025-12-08
- DOI
- https://doi.org/10.1080/08998280.2025.2591518
- Citations
- 1
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Edwards Lifesciences
- CryoLife
- Abiomed